CSL expects regulatory objection to Talecris bid

Australian vaccines and blood products developer CSL Ltd. said Monday that the U.S. Federal Trade Commission is likely to block its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics Inc.

0

0

Following protests among doctors and other government officials in Germany, women expecting babies are to be offered a swine flu vaccine without mercury and the adjuvant squalene made by CSL Biotherapies in Australia from Wednesday.

1

2

Shanghai Shenhua finally won their first home game of the CSL 2006 season at the fourth time of asking, prompting scenes of celebration both inside and outside Hongkou Stadium.

0

0